
Funding for research project on viral infections and Parkinson's disease
€100,000 from the German Society for Parkinson's Disease and Movement Disorders

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

€100,000 from the German Society for Parkinson's Disease and Movement Disorders

Important position for the head of the Computational Virology research group at TWINCORE

Two exciting days of science and networking with more than 150 participants
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Cabrera-Serrano A, Sánchez-Maldonado J, Rodríguez-Sevilla J, Reyes-Zurita F, Collado R, Puiggros A, Cornejo-Calvo E, García-Martín P, Ter Horst R, Benavente Y, Jerez A, Landi S, Espinet B, Maffei R, López-Nevot M, Ramos-Campoy S, González-Olmedo C, Chen-Liang T, Moreno V, Jannus F, Marcos-Gragera R, Carretero-Fernández M, Sampaio-Marques B, Gámez I, García-Álvarez M, Camp N, Dierssen-Sotos T, Kamaso J, Pérez E, Norman A, Luppi M, Li Y, Alcoceba M, Campa D, de San José S, Marasca R, Ludovico P, Clay-Gilmour A, Canzian F, Ibañez M, Netea M, McKay J, Casabonne D, Berndt S, Slager S, Sainz J
Bartsch Y, Webb N, Burgess E, Kang J, Lauffenburger D, Julg B
Buttler L, Velázquez-Ramírez D, Tiede A, Conradi A, Woltemate S, Geffers R, Bremer B, Spielmann V, Kahlhöfer J, Kraft A, Schlüter D, Wedemeyer H, Cornberg M, Falk C, Vital M, Maasoumy B
The project will investigate the immunological and genetic causes of vaccination failure in 5% of HBV-vaccinated individuals in order to develop new strategies to improve vaccination protection.
The project is developing methods to specifically transport antibiotics into cells such as alveolar macrophages, which are important in Mycobacterium tuberculosis infections. The aim is to overcome resistance and reduce side effects.
The project is developing iPSC-based therapies for MSMD patients, a genetic disease with mutations in the IFN-γ signaling pathway that lead to severe mycobacterial infections. The aim is to improve the treatment prognosis.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.

